Folate for Methylation Disorder

Verdict: Published with Warning

Across 6 PubMed studies, the evidence for Folate in Methylation Disorder grades Tier C — weak evidence. Effective, but with safety or population caveats.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.54
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
86%
Highly consistent evidence
Evidence level
E1
Cochrane high-quality SR/MA

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.65
L5 Clinical bodiesAuthoritative stance
0.72
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.542
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (6)L2 · primary research & systematic reviews

Homocysteine-lowering interventions for preventing cardiovascular events (Cochrane Review, 3rd update)
PMID: 28816346 2017 Cochrane Review n = 71,422
Finding: Folate-based homocysteine-lowering (B9 alone or with B6/B12) showed NO effect on myocardial infarction (RR 1.02, 95%CI 0.95-1.10) or all-cause mortality (RR 1.01, 95%CI 0.96-1.06) but a small reduction in stroke (RR 0.90, 95%CI 0.82-0.99), all high-quality evidence.
🟢 High quality Academic Effect size: MI RR 1.02 (0.95-1.10); all-cause death RR 1.01 (0.96-1.06); stroke RR 0.90 (0.82-0.99); I2=0-8%
View on PubMed
Folic acid supplementation for stroke prevention: A systematic review and meta-analysis of 21 randomized clinical trials worldwide
PMID: 38824900 2024 統合分析 n = 115,559
Finding: Folic acid supplementation significantly reduced stroke risk by 10% (RR 0.90, 95%CI 0.83-0.98), with benefit concentrated in non-fortified/partially-fortified regions (RR 0.83) and absent where grain is fortified (RR 1.04, P-interaction=0.003).
🟢 High quality Academic Effect size: Overall RR 0.90 (0.83-0.98); non-fortified RR 0.83 (0.75-0.93); fortified RR 1.04
View on PubMed
Meta Analysis of Methylenetetrahydrofolate Reductase (MTHFR) C677T polymorphism and its association with folate and colorectal cancer
PMID: 39875876 2025 統合分析 n = 95,420
Finding: MTHFR 677TT genotype was associated with lower CRC risk vs CC (OR 0.89, 95%CI 0.85-0.93, P<0.00001), and high folate intake was protective in TT carriers (OR 0.68, 95%CI 0.48-0.96, P=0.03), though authors caution on retrospective-study limitations.
Academic Effect size: TT vs CC OR 0.89 (0.85-0.93); high folate in TT OR 0.68 (0.48-0.96)
View on PubMed
The effects of folinic acid and l-methylfolate supplementation on serum total homocysteine levels in healthy adults
PMID: 38056998 2023 RCT (open-label) n = 272
Finding: Both folinic acid and l-methylfolate significantly lowered tHcy with no between-arm difference, and the reduction was significantly greater in MTHFR 677TT carriers; folinic acid raised serum folate more and outperformed l-methylfolate specifically in 677CT carriers.
Effect size: Not reported as a single quantitative effect size; genotype-modified tHcy reduction (TT > CT/CC), between-arm difference non-significant
View on PubMed
Association between serum 5-methyltetrahydrofolate and homocysteine in Chinese hypertensive participants with different MTHFR C677T polymorphisms: a cross-sectional study
PMID: 35562805 2022 Cross-sectional n = 2,328
Finding: Below 10 ng/mL, higher serum 5-MTHF was inversely associated with homocysteine, with the strongest effect in MTHFR 677TT carriers (TT beta=-1.19, P<0.001; CT beta=-0.20, P=0.011; CC beta=-0.14, P=0.087).
🟠 Limited quality Government Effect size: Per 1-ng/mL 5-MTHF: all beta=-0.50 (P<0.001); TT beta=-1.19; CT beta=-0.20; CC beta=-0.14 (NS)
View on PubMed
Supplementation with Folic Acid or 5-Methyltetrahydrofolate and Prevention of Neural Tube Defects: An Evidence-Based Narrative Review
PMID: 39339754 2024 系統性回顧
Finding: Folic acid has demonstrated NTD-prevention efficacy, but the authors conclude there are essentially NO clinical studies establishing 5-MTHF efficacy/dosage/safety for NTD prevention, so it cannot yet be recommended as an equivalent alternative.
🟠 Limited quality Academic Effect size: None (qualitative narrative review; explicitly notes absence of clinical efficacy data for 5-MTHF)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
Health claims relating folate to risk of neural tube defects may be made on the label or in labeling of foods, including dietary supplements, provided that the requirements in this section are met. source↗
L4b EU EFSA
Supportive
L4c UK NHS
Neutral
It's recommended that all women who could get pregnant should take a 400 microgram folic acid supplement daily before pregnancy and until they're 12 weeks pregnant. source↗
L4d TW TFDA / 衛福部
Supportive
孕期缺乏葉酸,會增加胎兒腦及脊髓先天性神經管缺陷的風險。育齡婦女及準備懷孕婦女可在準備階段每日攝取400微克,懷孕期間每日攝取600微克。 source↗
L4e WHO
Neutral
Current evidence suggests that folic acid supplementation in the periconceptional period, either alone or in combination with other vitamins and minerals, can prevent neural tube defects. source↗
L5a NIH Office of Dietary Supplements
Supportive
L5b Mayo Clinic
Neutral
There's no specific treatment for the gene change itself. If you have high homocysteine levels, treatment recommendations are the same whether you have a MTHFR variant or not. Your provider might recommend taking B6, B12 and folic acid supplements. source↗
L5c Cleveland Clinic
Supportive
You don't need special types of folate. ... You don't need to avoid folic acid. ... Pregnancy care providers usually recommend taking folic acid supplements before and during pregnancy. ... Your provider might recommend taking B6, B12 and folic acid supplements. source↗
L5e Specialty Society (condition-mapped)
Supportive
To lower homocysteine levels, your health care provider will usually recommend taking vitamin B supplements that include folic acid, which is a form of folate. However, if you have the gene variant MTHFR, your provider may recommend methylfolate (5-MTHF) instead since your body may be able to use this form more easily. Studies show that taking folic acid greatly reduces the risk of neural tube … source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬6 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-methylation-disorder-INT-folate-001 繁體中文版 →